TMCnet News
Eyenovia to Participate in Multiple Upcoming Medical MeetingsNEW YORK, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that it will be presenting at multiple eyecare meetings in October. Experts in optometry and ophthalmology as well as Eyenovia’s management team plans to highlight the Company’s late stage clinical pipeline, data from its MicroStat Phase III MIST-1 and MIST-2 studies for pharmacologic mydriasis, as well as new usability data generated from its MicroPine Phase III study in pediatric progressive myopia. “We are very excited to participate alongside our optometric and ophthalmic partners in several major upcoming eyecare meetings this fall and look forward to sharing further results from our MicroStat Phase III MIST-1 and MIST-2 studies with other industry leaders,” commented Dr. Sean Ianchulev, Eyenovia’s Chief Executive Officer and Chief Medical Officer. “In addition, we look forward to presenting compelling usability data from our ongoing MicroPine Phase III Chaperone study in pediatric progressive myopia, which we believe further supports the use of high precision microdosing for topical ocular therapies.” Details for the meetings are below: Meeting: Interventional Glaucoma Congress Panel Title: Drug Delivery Targets: Principles, Goals, Challenges Meeting: Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) Session Titl: Innovation Showcase 2 Date/Time: Thursday, October 10, 2019 at 10:11-10:18 a.m. PT Location: Hilton San Francisco Union Square, San Francisco, CA Meeting: American Academy of Ophthalmology (AAO) Date: Saturday, October 12 - Tuesday, October 15, 2019 Meeting: American Academy of Optometry’s 3rd World Congress of Optometry (AAOpt) Presentation: American Academy of Optometry Professional Press Conference Poster: Clinical Evaluation of a Micro-dosed Fixed Combination Phenylephrine 2.5%-Tropicamide 1% Ophthalmic Solution for Dilation of the Pupil in Two Randomized, Controlled Phase 3 Trials (MIST-1 & MIST-2) About Eyenovia Company Contact: Investor Contact: Media Contact: |